Can Rituximab Improve the Outcome of Patients with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma?
Open Access
- 1 March 2015
- journal article
- Published by S. Karger AG in Acta Haematologica
- Vol. 134 (3) , 187-192
Abstract
Background: Nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) is a rare subtype of Hodgkin's lymphoma showing strong CD20 expression. The role of rituximab in treating NLPHL still needs clarification. Methods: We retrospectively reviewed the outcome of 23 patients with NLPHL treated with rituximab alone or in combination with chemotherapy and/or radiotherapy as part of their first- or second-line treatment. Results: The median follow-up of the whole group was 67 months, and all patients remained alive. Twenty-two patients achieved complete remission after rituximab-based therapy, and one of them relapsed 32 months after treatment. One patient treated with rituximab alone achieved partial remission and progressed 22 months after treatment. Conclusion: The prognosis of NLPHL is excellent. Rituximab combined with chemotherapy and/or radiotherapy appears to prevent disease progression/relapse.Keywords
This publication has 15 references indexed in Scilit:
- The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)Blood, 2013
- Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study GroupBlood, 2011
- Lymphocyte-predominant Hodgkin lymphoma—clinical features and treatment outcomes from a 30-year experienceAnnals of Oncology, 2010
- Transformation to Aggressive Lymphoma in Nodular Lymphocyte-Predominant Hodgkin's LymphomaJournal of Clinical Oncology, 2010
- What Is the Appropriate Systemic Chemotherapy for Lymphocyte-Predominant Hodgkin's Lymphoma?Journal of Clinical Oncology, 2010
- Early-Stage, Lymphocyte-Predominant Hodgkin's Lymphoma: Patient Outcomes From a Large, Single-Institution Series With Long Follow-UpJournal of Clinical Oncology, 2010
- Nodular, lymphocyte‐predominant Hodgkin lymphomaCancer, 2009
- Lymphocyte-Predominant and Classical Hodgkin's Lymphoma: A Comprehensive Analysis From the German Hodgkin Study GroupJournal of Clinical Oncology, 2008
- Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)Blood, 2008
- Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG)Annals of Oncology, 2005